Survival analysis of veteran patients with pancreatic cancer
- 1 June 2016
- journal article
- research article
- Published by Wiley in Journal of Digestive Diseases
- Vol. 17 (6) , 399-407
Abstract
Objective: For patients with pancreatic cancer, the identification of reliable predictors of their outcomes could be invaluable for directing the managements. This study aimed to identify clinical and laboratory factors that could be used to predict early (≤6 months) or late (>6 months) mortality.Methods: Medical records of patients diagnosed with pancreatic cancer in the VA North Texas Health Care System from 2005 to 2010 were retrospectively reviewed. Univariate and multivariate analyses (MVA) were performed and the utility of cancer antigen 19‐9 (CA19‐9) test was explored.Results: Altogether 109 patients with pancreatic cancer, 89.0% of whom were with adenocarcinoma, were divided into early (n = 62) and late (n = 47) mortality groups. Kaplan–Meier analysis revealed a median survival of 154 days [95% confidence interval (CI) 93–194 days]. On MVA, abdominal pain (OR = 10.6, P = 0.009) and large tumor size (OR = 2.4, P = 0.028) were significantly associated with early mortality, while palliative chemotherapy (OR = 0.048, P = 0.001) and neuroendocrine tumor (OR = 0.009, P = 0.024) were significantly associated with late mortality. Subgroup analyses of adenocarcinoma and late‐stage patients revealed similar results. Serum CA19‐9 performed poorly as a prognostic indicator in both groups (P = 0.43), in metastatic disease at diagnosis (P = 0.32) and after treatment (P = 0.65).Conclusions: Abdominal pain and large tumor size portends a poor prognosis in patients with pancreatic cancer. Palliative chemotherapy and surgical intervention may prolong the patient's survival. CA19‐9 is not universally reliable for predicting metastasis, survival, or the responses to chemotherapy.Keywords
This publication has 36 references indexed in Scilit:
- Association between Helicobacter pylori Infection and Pancreatic Cancer Development: A Meta-AnalysisPLOS ONE, 2013
- ABO Blood Group and the Risk of Pancreatic CancerJNCI: Journal of the National Cancer Institute, 2009
- Validation of the 6th edition AJCC pancreatic cancer staging systemCancer, 2007
- Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapyBritish Journal of Cancer, 2007
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- Nonductal neoplasms of the pancreasLaboratory Investigation, 2007
- ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal CancerJournal of Clinical Oncology, 2006
- 1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution ExperienceJournal of Gastrointestinal Surgery, 2006
- Differences in Survival by Histologic Type of Pancreatic CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysisCancer, 1993